A Structurally Stabilized Lipopolymer Nanoplatform Targeting Pan‐Tissue Antigen‐Presenting Cells Enables Durable in situ mRNA Cancer ImmunotherapyL L Zeng, Xuesi Chen, Qian Shen et al.|Advanced Materials|2026Cited by 0
Lipid tail heterogeneity enables organ-selective mRNA delivery for in vivo CRISPR-Cas9 gene editingJing Liao, Jinjin Chen, Joseph Harmon et al.|Materials Today|2026Cited by 0